Diamyd Medical AB announced that it recently acquired exclusive rights relating to the therapeutic use of GABA for the treatment of diabetes and other inflammation-related conditions. The company is now expanding its Scientific and Medical Advisory Board with three internationally leading experts on GABA and diabetes: Dr. Bryndis Birnir, Dr. Brooke Ligon, and Dr. Qinghua Wang. Diamyd Medical has for a long time attracted some of the most renowned experts in diabetes and immunology to its Scientific and Medical Advisory Board.

The advisory board is an important source of information for the Company, which regularly consults with individual members concerning medical and scientific questions that arise in Diamyd's activities. In addition, the members serve as Diamyd's ambassadors towards researchers in academia and industry. Bryndis Birnir is Professor of Physiology within the Medical Faculty at Uppsala University.

Dr. Birnir's research is focused on GABA signaling where she and her colleagues study the interplay between the extracellular signal molecule GABA and the high-affinity GABA-A receptors that are ion channels. In particular they focus on how these molecules affect secretion of metabolic hormones, cellular excitability and immune modulation.